A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Olaparib (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 21 Aug 2024 Planned End Date changed from 21 Aug 2024 to 16 Dec 2025.
- 21 Aug 2024 Planned primary completion date changed from 21 Aug 2024 to 16 Dec 2025.
- 25 Aug 2023 Planned number of patients changed from 60 to 150.